Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

See all formats and pricing


Select Volume and Issue


The entero-insular axis: implications for human metabolism

Lakshminarayan R. Ranganath1

1Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK

Corresponding author: L.R. Ranganath, MD, PhD, FRCPE, FRCPath, Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 46, Issue 1, Pages 43–56, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2008.008, November 2007

Publication History

Published Online:


Incretins such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are intestinal hormones that are released in response to ingestion of nutrients, especially carbohydrate. They have a number of important biological effects, which include release of insulin, inhibition of glucagon and somatostatin, maintenance of β-cell mass, delay of gastric emptying, and inhibition of feeding. These properties allow them to be potentially suitable agents for the treatment of type 2 diabetes (T2D). Incretin receptors are also present in other parts of the body including the brain, where their effects are beginning to be understood and their relevance to disorders of nutrition and ageing are being explored.

There is currently a pandemic of obesity and diabetes, and existing treatments are largely inadequate in regard to efficacy as well as their ability to tackle important factors in the pathogenesis of T2D. There is increasing evidence that current treatments do not address the issue of progressive β-cell failure in T2D. As obesity is the engine that is driving the epidemic of diabetes, it is disappointing that most treatments that succeed in lowering plasma glucose are also associated with weight gain. It is now well established that intensively treated T2D has a better outcome than standard treatment. Consequently, achieving better control of diabetes with lower HbA1c is the goal of optimal treatment. Despite the use of usual therapeutic agents in T2D, often in high doses and as combinations, such as metformin, sulphonylurea, α-glycosidase inhibitors, thiazolidinediones and a number of animal and human insulin preparations, optimal control of glycaemia is not achieved.

The use of incretins as therapeutic agents offers a new approach to the treatment of T2D. Incretin metabolism is abnormal in T2D, evidenced by a decreased incretin effect, reduction in nutrient-mediated secretion of GIP and GLP-1 in T2D, and resistance to GIP. GLP-1, on the other hand, when administered intravenously in T2D is able to increase insulin secretion and improve glucose homeostasis. As GLP-1 has a very short half-life, due to rapid degradation by the enzyme dipeptidyl peptidase IV (DPPIV), analogues of GIP and GLP-1 that are resistant to the action of DPPIV have been developed and clinical trials have shown their effectiveness. Another novel agent, naturally resistant to DPPIV that is given by subcutaneous injection is a synthetic peptide called exenatide, has recently been approved for treatment of T2D in the USA. Efforts are underway to develop agents that can be given orally and include a DPPIV inhibitor that has been licensed for the treatment of T2D in the USA, and several other agents are undergoing clinical trials. Strategies to augment the biological actions of GIP and/or GLP-1 in T2D are expected to minimise weight gain, reduce hypoglycaemic episodes and prevent progressive β-cell failure by increasing β-cell mass. The optimal agent(s) that may mimic and replace the endogenous incretin effect is not fully known and awaits the outcome of clinical trials that are still ongoing. The potential therapeutic role in non-diabetic states, including obesity and neurodegenerative disease, is intriguing and depends upon results from ongoing research.

Clin Chem Lab Med 2008;46:43–56.

Keywords: adipose tissue; β-cells; bone; brain; diabetes; dipeptidyl peptidase IV (DPPIV); exendin-4; glucagon-like peptide 1 (GLP-1); glucose; glucose-dependent insulinotropic polypeptide (GIP); incretins; insulin; liver; metabolism

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

A.A. Spasov and N.I. Chepljaeva
Biomeditsinskaya Khimiya, 2015, Volume 61, Number 4, Page 488
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, and Flávio Reis
Journal of Diabetes Research, 2015, Volume 2015, Page 1
A. A. Spasov and N. I. Chepljaeva
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2014, Volume 8, Number 4, Page 293
Z. Zhu, X. Yang, K. Wang, Z. Wang, Y. Zhao, and M. Yu
European Surgery, 2014, Volume 46, Number 5, Page 189
Francieli Rohden, Cintia S. Costa, Thais O. Hammes, Rogério Margis, Alexandre V. Padoin, Cláudio C. Mottin, and Regina Maria Guaragna
Obesity Surgery, 2014, Volume 24, Number 12, Page 2075
Tom Gerner, Odd-Erik Johansen, Mona Olufsen, Peter A. Torjesen, and Arnljot Tveit
Scandinavian Journal of Clinical & Laboratory Investigation, 2014, Volume 74, Number 3, Page 213
Simone Wahl, Susanne Krug, Cornelia Then, Anna Kirchhofer, Gabi Kastenmüller, Tina Brand, Thomas Skurk, Melina Claussnitzer, Cornelia Huth, Margit Heier, Christa Meisinger, Annette Peters, Barbara Thorand, Christian Gieger, Cornelia Prehn, Werner Römisch-Margl, Jerzy Adamski, Karsten Suhre, Thomas Illig, Harald Grallert, Helmut Laumen, Jochen Seissler, and Hans Hauner
Metabolomics, 2014, Volume 10, Number 3, Page 386
Stacey MacNeil, Rachel M. Rebry, Ian J. Tetlow, Michael J. Emes, Bruce McKeown, and Terry E. Graham
Applied Physiology, Nutrition, and Metabolism, 2013, Volume 38, Number 12, Page 1187
J J Holst
International Journal of Obesity, 2013, Volume 37, Number 9, Page 1161
H. Kahleova, A. Mari, V. Nofrate, M. Matoulek, L. Kazdova, M. Hill, and T. Pelikanova
Journal of Diabetes and its Complications, 2012, Volume 26, Number 5, Page 442
Chih-Yen Chen, Mineko Fujimiya, Alessandro Laviano, Full-Young Chang, Han-Chieh Lin, and Shou-Dong Lee
Journal of the Chinese Medical Association, 2010, Volume 73, Number 5, Page 225
Daniel Eberhard and Eckhard Lammert
Current Opinion in Genetics & Development, 2009, Volume 19, Number 5, Page 469
Natalia C. Habib, Stella Maris Honoré, Susana B. Genta, and Sara S. Sánchez
Chemico-Biological Interactions, 2011, Volume 194, Number 1, Page 31
Maria P. Yavropoulou, Kalliopi Kotsa, Isaak Kesisoglou, Olympia Anastasiou, and John G. Yovos
Peptides, 2008, Volume 29, Number 12, Page 2281
Herbert D. Spapen, Rita Jacobs, Elisabeth De Waele, and Patrick M. Honoré
Critical Care Medicine, 2011, Volume 39, Number 6, Page 1551
Hiroshi Kobayashi, Yoshihiko Yamada, Seiji Kanayama, Naoto Furukawa, Taketoshi Noguchi, Shoji Haruta, Shozo Yoshida, Mariko Sakata, Toshiyuki Sado, and Hidekazu Oi
International Journal of Gynecological Cancer, 2009, Volume 19, Number 3, Page 471

Comments (0)

Please log in or register to comment.